FIN-SGLT2-HFFinerenone and SGLT2 Inhibitor Combination for Heart Failure

Heart failure is a long-term condition that significantly impacts quality of life and causes a heavy burden on healthcare systems, despite advances in treatments. While a type of medication called Sodium-glucose cotransporter-2 (SGLT2) inhibitors have shown benefits for heart failure patients, there's still a need for additional treatments to further improve outcomes. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has shown promise in reducing inflammation and fibrosis, and providing cardiovascular benefits in patients with chronic cardiovascular and renal diseases. This study aims to explore if combining Finerenone with SGLT2 inhibitors can offer additional benefits and improve care for heart failure patients. In this controlled pilot study, researchers will evaluate the effects and safety of adding Finerenone to the standard therapy with an SGLT2 inhibitor in heart failure patients, compared to treatment using an SGLT2 inhibitor alone. Patients who are already on stable SGLT2 inhibitor therapy will continue their treatment as assigned and will be monitored throughout the study period. The main goal is to assess the incidence of cardiovascular mortality and hospitalization due to heart failure in each treatment group. This will help understand the potential benefits and tolerability of combining Finerenone with SGLT2 inhibitors for heart failure patients and guide the design of future larger-scale studies.